---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-025522"
form_type: "8-K"
ticker: "ZLAB"
cik: "0001704292"
company_name: "Zai Lab Ltd"
filed_at: "2022-09-27T23:59:59+00:00"
generated_at: "2026-06-23T07:16:36.833400+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zai Lab licenses TIVDAK from Seagen for China, HK, Macau, Taiwan; $30M upfront plus milestones up to $263M

## Summary
- Zai Lab pays $30M upfront, up to $78M in dev/reg milestones, and up to $185M in sales milestones.
- Seagen receives tiered royalties from mid-teens to low twenties on net sales in licensed territory.
- Payments shared 50/50 with Genmab under existing Seagen/Genmab co-development agreement.
- TIVDAK is FDA-approved for recurrent/metastatic cervical cancer; Phase 3 trial (innovaTV 301) ongoing.
- Approximately 110,000 new cervical cancer cases annually in China, representing significant unmet need.

## SEC filing metadata
- accession: 0001628280-22-025522
- form_type: 8-K
- ticker: ZLAB
- cik: 0001704292
- company_name: Zai Lab Ltd
- filed_at: 2022-09-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704292/000162828022025522/0001628280-22-025522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704292/000162828022025522/zlab-20220923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-025522
- JSON: https://secwatch.observer/filing/0001628280-22-025522.json
- Plain text: https://secwatch.observer/filing/0001628280-22-025522.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.